Immediate Impact
54 standout
Citing Papers
Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
2025 Standout
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Works of Abraham Jacob being referenced
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2020 Standout
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Abraham Jacob | 358 | 65 | 282 | 144 | 32 | 574 | |
| Yukari Shirasugi | 216 | 29 | 233 | 320 | 39 | 613 | |
| Yvonne Loh | 130 | 27 | 224 | 226 | 32 | 594 | |
| Pinhas Stark | 284 | 47 | 86 | 198 | 31 | 587 | |
| S Nati | 165 | 20 | 261 | 210 | 46 | 541 | |
| Eleonora Russo | 140 | 19 | 184 | 199 | 28 | 525 | |
| Anjum Hassan | 91 | 88 | 216 | 111 | 39 | 526 | |
| Atsushi Notoya | 91 | 28 | 166 | 137 | 27 | 474 | |
| Guido Gini | 89 | 36 | 233 | 180 | 36 | 612 | |
| Nak Gyun Chung | 122 | 86 | 119 | 144 | 36 | 567 | |
| Carla Pieresca | 145 | 46 | 359 | 99 | 23 | 480 |
All Works
Login with ORCID to disown or claim papers
Loading papers...